Saltar al contenido
MilliporeSigma
  • Clonal heterogeneity of thymic B cells from early-onset myasthenia gravis patients with antibodies against the acetylcholine receptor.

Clonal heterogeneity of thymic B cells from early-onset myasthenia gravis patients with antibodies against the acetylcholine receptor.

Journal of autoimmunity (2014-01-21)
Kathleen Vrolix, Judith Fraussen, Mario Losen, Jo Stevens, Konstantinos Lazaridis, Peter C Molenaar, Veerle Somers, Maria Alma Bracho, Rozen Le Panse, Piet Stinissen, Sonia Berrih-Aknin, Jos G Maessen, Leen Van Garsse, Wim A Buurman, Socrates J Tzartos, Marc H De Baets, Pilar Martinez-Martinez
RESUMEN

Myasthenia gravis (MG) with antibodies against the acetylcholine receptor (AChR-MG) is considered as a prototypic autoimmune disease. The thymus is important in the pathophysiology of the disease since thymus hyperplasia is a characteristic of early-onset AChR-MG and patients often improve after thymectomy. We hypothesized that thymic B cell and antibody repertoires of AChR-MG patients differ intrinsically from those of control individuals. Using immortalization with Epstein-Barr Virus and Toll-like receptor 9 activation, we isolated and characterized monoclonal B cell lines from 5 MG patients and 8 controls. Only 2 of 570 immortalized B cell clones from MG patients produced antibodies against the AChR (both clones were from the same patient), suggesting that AChR-specific B cells are not enriched in the thymus. Surprisingly, many B cell lines from both AChR-MG and control thymus samples displayed reactivity against striated muscle proteins. Striational antibodies were produced by 15% of B cell clones from AChR-MG versus 6% in control thymus. The IgVH gene sequence analysis showed remarkable similarities, concerning VH family gene distribution, mutation frequency and CDR3 composition, between B cells of AChR-MG patients and controls. MG patients showed clear evidence of clonal B cell expansion in contrast to controls. In this latter aspect, MG resembles multiple sclerosis and clinically isolated syndrome, but differs from systemic lupus erythematosus. Our results support an antigen driven immune response in the MG thymus, but the paucity of AChR-specific B cells, in combination with the observed polyclonal expansions suggest a more diverse immune response than expected.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Formamida, ReagentPlus®, ≥99.0% (GC)
Sigma-Aldrich
Piruvato sódico, powder, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥99%
Sigma-Aldrich
Formamida, ≥99.5% (GC), BioReagent, for molecular biology
Sigma-Aldrich
Formamida, BioUltra, for molecular biology, ≥99.5% (T)
Sigma-Aldrich
Acida sódica, BioUltra, ≥99.5% (T)
Sigma-Aldrich
Acida sódica, purum p.a., ≥99.0% (T)
Sigma-Aldrich
Piruvato sódico, Hybri-Max, powder, suitable for hybridoma
Sigma-Aldrich
Piruvato sódico, powder, BioXtra, suitable for mouse embryo cell culture
Sigma-Aldrich
Acida sódica, ReagentPlus®, ≥99.5%
Sigma-Aldrich
Formamida, spectrophotometric grade, ≥99%
Sigma-Aldrich
Piruvato sódico, ReagentPlus®, ≥99%
Sigma-Aldrich
Acida sódica, BioXtra
Sigma-Aldrich
Formamida, JIS special grade, ≥98.5%
Sigma-Aldrich
Formamide solution, NMR reference standard, 90% in DMSO-d6 (99.9 atom % D), NMR tube size 10 mm × 8 in.
Sigma-Aldrich
Formamida, ACS reagent, ≥99.5%
Supelco
Formamide solution, NMR reference standard, 90% in DMSO-d6 (99.9 atom % D), NMR tube size 5 mm × 8 in.
Sigma-Aldrich
Piruvato sódico, BioXtra, ≥99%
Sigma-Aldrich
Formamida, SAJ first grade, ≥98.5%
Sigma-Aldrich
Piruvato sódico, SAJ special grade, ≥95.0%
Sigma-Aldrich
Acida sódica, SAJ first grade, ≥97.0%
Sigma-Aldrich
Piruvato sódico, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, ≥99%
Supelco
Formamide solution, NMR reference standard, 90% in DMSO-d6 (99.9 atom % D), NMR tube size 5 mm × 8 in.